| 前收市價 | 200.24 |
| 開市 | 200.64 |
| 買盤 | 80.23 x 1300 |
| 賣出價 | 200.65 x 800 |
| 今日波幅 | 198.22 - 201.74 |
| 52 週波幅 | 180.54 - 254.00 |
| 成交量 | |
| 平均成交量 | 480,812 |
| 市值 | 19.843B |
| Beta 值 (5 年，每月) | 0.79 |
| 市盈率 (最近 12 個月) | 35.35 |
| 每股盈利 (最近 12 個月) | 5.68 |
| 業績公佈日 | 2024年5月08日 - 2024年5月13日 |
| 遠期股息及收益率 | 2.08 (1.04%) |
| 除息日 | 2024年2月22日 |
| 1 年預測目標價 | 241.29 |
ZacksZacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
Zacks3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
ZacksHere's Why Steris (STE) is Poised for a Turnaround After Losing -9.06% in 4 Weeks
The heavy selling pressure might have exhausted for Steris (STE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
